Antimicrobial

Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327

Results demonstrate efficacy on bacterial growth in participants injected with RECCE® 327 (R327) at the highest tested dose of 4,000mgNo...

Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections

Positions RECCE® 327 (R327) gel as a potential broad topical therapeutic for all bacterial skin infectionsHuman Research Ethics Committee approval...

Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development

Inclusion underscores significance of RECCE® 327 (R327) in combating antimicrobial resistance and its potential to treat broad range of life-threatening...

AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim

AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June...

Covalon Presents Compassionate Care Technology at the Infusion Nurses Society (INS) Annual Meeting & Exhibition in Kansas City, MO

Visit Covalon at booth 420 to discover the latest in compassionate vascular access solutionsMISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company"...

Recce Pharmaceuticals Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial

First participants (male/female) dosed at 4,000mg over 20 minutes, with remaining subjects to be dosed in the near future -...

error: Content is protected !!